Who's excited about #CancerTechShow24? Not sure what we're talking about? Want to know what's new this year? Check out our post highlighting the upcoming event we're hosting with National Cancer Institute (NCI) Technology Transfer Center all about technological innovation and partnerships:
Frederick National Laboratory for Cancer Research
Biotechnology Research
Frederick, Maryland 9,268 followers
Discovery, innovation and success in the biomedical sciences.
About us
The Frederick National Laboratory is dedicated to improving human health through discovery and innovation in the biomedical sciences, focusing on cancer, AIDS, and emerging infectious diseases. Career opportunities: https://frederick.cancer.gov/careers
- Website
-
https://frederick.cancer.gov
External link for Frederick National Laboratory for Cancer Research
- Industry
- Biotechnology Research
- Company size
- 1,001-5,000 employees
- Headquarters
- Frederick, Maryland
- Type
- Partnership
- Founded
- 1972
Locations
-
Primary
8560 Progress Dr
Frederick, Maryland 21701, US
Employees at Frederick National Laboratory for Cancer Research
-
Chris Karlovich
Director of the Molecular Characterization Lab (MoCha) at Frederick National Laboratory for Cancer Research
-
Elaine Freund
Scientific Project Manager II at Frederick National Lab
-
Carolyn Kelley Klinger
Technical writer at Frederick National Laboratory for Cancer Research
-
Todd Pihl
Updates
-
After decades of progress, people with #HIV now have access to drugs that keep the virus undetectable and thus under control with simple one-pill-a-day treatments of antiretroviral therapy (ART). 👏 But if treatment is stopped, the virus resumes replicating, what scientists call the Rebound Competent Viral Reservoir. A new study from the AIDS and Cancer Virus Program and colleagues offers guidance for targeting the HIV viral reservoir, the major obstacle to more definitive treatment or even cure of HIV infection: https://heyor.ca/dsugbl
Study offers guidance for targeting HIV's viral reservoir | Frederick National Laboratory
-
New and improved: The NCI60 human tumor cell line screen, which has been available as a resource to the #CancerResearch community for 30+ years, launched into a new phase this month. The HTS384 NCI60 screen shows robust patterns of response to oncology agents and substantial overlap with the classic screen, providing an updated tool for studying therapeutic agents. Although the cell lines remain the same, the updated screen is performed with 384-well plates, a 3-day exposure period to test agents, and a luminescent endpoint to measure cell viability based upon cellular ATP content.
HTS384 NCI60: The Next Phase of the NCI60 Screen - PubMed
pubmed.ncbi.nlm.nih.gov
-
Check out this study featuring our Nanotechnology Characterization Laboratory: A lack of accurate models poses challenges to identifying toxicity during preclinical studies caused by hand and foot syndrome, which limits the successful therapeutic applications of anticancer drugs. Reliable models would enable detection of this toxicity early during the drug development process. So, the team demonstrated the utility of an in vitro skin explant assay to detect inflammatory and drug-mediated skin damage consistent with the condition.
Our recent study "In vitro assessment of nanomedicines' propensity to cause palmar-plantar erythrodysesthesia: A Doxil vs. doxorubicin case study" has been published in Nanomedicine NBM: https://lnkd.in/exaXM32g Congratulations and many thanks to the interdisciplinary team: Edward Cedrone, Emma Grabarnick (Portnoy) B.Pharm Ph.D, Abbas Ishaq, Elijah Edmondson, DVM PhD, Sarah Skoczen, Barry Neun, Siannah Cawkwell, Matthew Freer, Lisbet Sviland, and Anne Dickinson. Alcyomics Team, it's been a pleasure working with you.
-
Looking forward to the keynote address by Maryland Tech Council's Steven Walker during #CancerTechShow24 on Sept. 4. Register today for this unique (and free!) opportunity to network and learn how to partner with the National Cancer Institute (NCI) and Frederick National Laboratory: https://heyor.ca/5cmPHG
-
-
#DYK we help collect, process, and manage valuable resources for the research community that cover an array of fields and research needs? Learn more 👉 https://heyor.ca/om4z9i
-
-
When asked what he enjoys about working at the Frederick National Laboratory, Chris said, “Firstly, the people in the MoCha lab are fantastic. They are dedicated to our mission here at FNL and are incredibly bright. An exciting aspect of our work is the implementation of cutting-edge technologies to gain new insights into cancer biology.” To find out more about the exciting work our Molecular Characterization Laboratory does at FNL, visit: https://heyor.ca/J7KwlH #FNLProud #CancerResearch
-
-
Submit your abstract for the #RAS Initiative Symposium by September 1st at 11:59 PM: https://heyor.ca/8sr6Vw All submissions will be peer reviewed, with outstanding abstracts selected for short talks. We strongly encourage trainees and early-career researchers to submit. This is a fantastic chance to gain valuable feedback from top scientists in the field!
-
-
Business opportunity! Stable Clone Production for Anti-CD6 Monoclonal Antibodies. Questions due: Sept. 2 at 1 p.m. Offers due: Sept. 23 at 1 p.m. 🤝 Learn more: https://lnkd.in/e7ehFRgg
Stable Clone Production for Anti-CD6 Monoclonal Antibodies | Frederick National Laboratory
frederick.cancer.gov
-
Global HIV/AIDS experts whose groundbreaking research has significantly advanced our understanding of HIV disease, including Salim Abdool Karim, Ph.D. and Anthony S. Fauci, M.D. will speak at the “HIV in 2024: Progress, Problems and Prospects” scientific symposium in Frederick, Maryland. The event, co-hosted by Hood College and the Frederick National Laboratory, will be held Sept. 23-25 on the Hood campus. Registration is required: https://heyor.ca/SYK9yN #HIVS2024
-